Cellular and cytokine responses of the human central nervous system to intracranial administration of tumor necrosis factor alpha for the treatment of malignant gliomas.
To elucidate the role of tumor necrosis factor alpha (TNF alpha) as a biological response modifier, we studied cellular and cytokine responses of the central nervous system to TNF alpha administered intracranially in a phase I clinical trial for patients with malignant gliomas. Six patients received injections of TNF alpha (1.25 x 10(3)-10 x 10(3) U/injection) into the tumor cavities, and regional fluids (RF) and lumbar cerebrospinal fluids (CF) were serially sampled before and after the injections. Recruitment of neutrophils occurred, mostly peaking 8 h after TNF alpha injection, and fewer numbers of CD4+ T cells and monocytes/macrophages migrated, subsequently peaking at 24 h. The CF leukocytosis persisted for 48 h and was associated with an increased level of neutrophil chemotactic activity in the CF. This neutrophil chemotactic activity was attributed to interleukin-8 (IL-8) by HPLC. The level of IL-6 activity in the CF and RF consistently increased; beginning 2 h after TNF alpha injection and reaching the maximum between 8 h and 12 h. It returned to the basal level within 48 h. IL-1 beta was detected in the CF of three patients, its level peaking at 8 h. Prostaglandin E2 also increased after injection of TNF alpha, peaking between 4 h and 12 h and then gradually decreasing. Transforming growth factor beta was found in all cases tested and one patient showed a significant change after TNF alpha injection. IL-2 activity, interferon alpha (INF alpha) activity, IFN beta, and granulocyte/macrophage-colony-stimulating factor were not detected in the CF or RF. In conclusion, TNF alpha is biologically effective in inducing migration of immune cells and generating multiple cytokine responses in the human central nervous system.
Tada
M
M
Department of Neurosurgery, Hokkaido University School of Medicine, Sapporo, Japan.
Sawamura
Y
Y
Sakuma
S
S
Suzuki
K
K
Ohta
H
H
Aida
T
T
Abe
H
H
D000328:Adult; D002634:Chemotaxis, Leukocyte; D015232:Dinoprostone / Q000134:cerebrospinal fluid; D005910:Glioma / Q000628:therapy*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000134:cerebrospinal fluid; D006801:Humans; D007372:Interferons / Q000134:cerebrospinal fluid; D007375:Interleukin-1 / Q000134:cerebrospinal fluid; D007376:Interleukin-2 / Q000134:cerebrospinal fluid; D015850:Interleukin-6 / Q000134:cerebrospinal fluid; D008875:Middle Aged; D009504:Neutrophils / Q000276:immunology; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000134:cerebrospinal fluid; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage* / Q000134:cerebrospinal fluid
D007375:Interleukin-1; D007376:Interleukin-2; D015850:Interleukin-6; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D007372:Interferons; D015232:Dinoprostone